Adverse Drug Reaction Reporting Systems
"Adverse Drug Reaction Reporting Systems" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
Descriptor ID |
D016907
|
MeSH Number(s) |
E05.337.800.120 N02.421.668.320.120
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adverse Drug Reaction Reporting Systems".
Below are MeSH descriptors whose meaning is more specific than "Adverse Drug Reaction Reporting Systems".
This graph shows the total number of publications written about "Adverse Drug Reaction Reporting Systems" by people in this website by year, and whether "Adverse Drug Reaction Reporting Systems" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2005 | 1 | 0 | 1 |
2007 | 2 | 0 | 2 |
2008 | 0 | 1 | 1 |
2009 | 1 | 1 | 2 |
2011 | 6 | 3 | 9 |
2012 | 1 | 4 | 5 |
2013 | 3 | 2 | 5 |
2014 | 3 | 3 | 6 |
2015 | 1 | 0 | 1 |
2016 | 1 | 1 | 2 |
2017 | 3 | 2 | 5 |
2019 | 1 | 1 | 2 |
2020 | 0 | 1 | 1 |
2021 | 0 | 5 | 5 |
2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adverse Drug Reaction Reporting Systems" by people in Profiles.
-
Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic. JAMA Oncol. 2022 12 01; 8(12):1849-1851.
-
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(3):90-95.
-
The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1545-1552.
-
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 13; 70(32):1094-1099.
-
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 09; 70(27):977-982.
-
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 30; 70(17):651-656.
-
Simplifying ADR Reporting: A Worthy Goal, but the Devil is in the Details. Clin Gastroenterol Hepatol. 2021 09; 19(9):1793-1795.
-
Sensorineural hearing loss (SNHL) as an adverse event following immunization (AEFI): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2020 06 19; 38(30):4717-4731.
-
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
-
Leveraging the entire cohort in drug safety monitoring: part 1 methods for sequential surveillance that use regression adjustment or weighting to control confounding in a multisite, rare event, distributed data setting. J Clin Epidemiol. 2019 08; 112:77-86.